Overall, the interim results of the ongoing INCIPIENT study provide proof of principle for CAR-T cell targeting of multiple tumor cell-associated surface antigens, substantiate EGFR as treatment target of interest, provide initial safety data for intraventricular application and indicate potential antitumor efficacy for the CARv3-TEAM-E construct. The gene discussed is EGFR; the disease is neoplasm.